Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial

Detalles Bibliográficos
Autores principales: Devos, Timothy, Geukens, Tatjana, Schauwvlieghe, Alexander, Ariën, Kevin K., Barbezange, Cyril, Cleeren, Myriam, Compernolle, Veerle, Dauby, Nicolas, Desmecht, Daniël, Grimaldi, David, Lambrecht, Bart N., Luyten, Anne, Maes, Piet, Moutschen, Michel, Romano, Marta, Seyler, Lucie, Nevessignsky, Michel Toungouz, Vandenberghe, Katleen, van Griensven, Johan, Verbeke, Geert, Vlieghe, Erika, Yombi, Jean Cyr, Liesenborghs, Laurens, Verhamme, Peter, Meyfroidt, Geert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734912/
https://www.ncbi.nlm.nih.gov/pubmed/33317581
http://dx.doi.org/10.1186/s13063-020-04947-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734912/
https://www.ncbi.nlm.nih.gov/pubmed/33317581
http://dx.doi.org/10.1186/s13063-020-04947-2

Ejemplares similares